SENTI-202

Phase 1Active

0 views this week 0 watching💤 Quiet

Interest: 23/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

AML/MDS

Conditions

AML/MDS, CD33 Expressing Hematological Malignancies, FLT3 Expressing Hematological Malignancies

Trial Timeline

Apr 22, 2024 → Aug 1, 2040

NCT ID

NCT06325748

About SENTI-202

SENTI-202 is a phase 1 stage product being developed by Senti Biosciences for AML/MDS. The current trial status is active. This product is registered under clinical trial identifier NCT06325748. Target conditions include AML/MDS, CD33 Expressing Hematological Malignancies, FLT3 Expressing Hematological Malignancies.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06325748	Phase 1	Active	Apr 22, 2024	Aug 1, 2040	AML/MDS